Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01150760
First received: June 23, 2010
Last updated: September 8, 2010
Last verified: September 2010

June 23, 2010
September 8, 2010
April 2010
August 2010   (final data collection date for primary outcome measure)
  • Percentage of Patients Who Died [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    All-cause
  • Percentage of Patients With Reported In-hospital Postoperative Gastrointestinal (GI) Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    GI morbidity will be identified using International Classification of Disease 9th Edition Clinical Modification (ICD-9-CM) diagnosis and procedure codes for paralytic ileus, flatulence, eructation, gas pain, insertion of a nasogastric tube, total parenteral nutrition, peripheral parenteral nutrition, digestive symptom complications, diarrhea following GI surgery, intestinal obstruction, abdominal pain, peritoneal adhesions, unspecified protein-calorie malnutrition, parenteral infusion of concentrated nutritional substances, or enteral infusion of concentrated nutritional substances.
  • Percentage of Patients With In-hospital Cardiovascular Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Cardiovascular morbidity was identified using ICD-9-CM diagnosis and procedure codes for myocardial infarction; other ischemic events; congestive heart failure and shock; arrhythmias; or other cardiovascular events (cardiac complications, peripheral vascular complications).
  • Percentage of Patients With In-hospital Cerebrovascular Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Cerebrovascular morbidity was identified using ICD-9-CM diagnosis and procedure codes for ischemic, thrombotic, embolic or hemorrhagic cerebrovascular accidents; acute but ill-defined cerebrovascular disease; transient cerebral ischemia; syncope; or postoperative cerebrovascular accident.
  • Percentage of Patients With In-hospital Pulmonary Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Pulmonary morbidity was identified using ICD-9-CM diagnosis and procedure codes for pneumonia; infectious pneumonia; respiratory complications, pulmonary collapse; acute respiratory failure or edema; pulmonary congestion and hypostasis; pulmonary/respiratory insufficiency after trauma and/or surgery; dyspnea; or respiratory arrest; transfusion related acute lung injury.
  • Percentage of Patients With In-hospital Infection Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Infection morbidity was identified using ICD-9-CM diagnosis and procedure codes for infection due to central venous catheter; abscess of intestine; peritoneal abscess; sepsis or severe sepsis; infection due to vascular device, implant and graft; urinary tract infection; disruption of internal or external surgical wound; persistent postoperative fistula; or postoperative infection.
  • Percentage of Patients With In-hospital Thromboembolic Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Thromboembolic morbidity was identified using ICD-9-CM diagnosis and procedure codes for pulmonary embolishm and infarction; arterial embolism and thrombosis or thrombosis of the lower extremities; vascular disorders of the kidney; acute vascular insufficiency of the intestine; or venous thromboembolism.
  • Percentage of Patients With In-hospital Other Morbidity [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Other morbidity was identified using ICD-9-CM diagnosis and procedure codes for disruption of wound, decubitus ulcer, or postoperative complicaitons not elsewhere classified.
  • Percentage of Patients Who Were Readmitted Within 15 Days of Discharge [ Time Frame: Within 15 days of discharge from hospitalization for bowel resection ] [ Designated as safety issue: No ]
  • Percentage of Patients Who Were Readmitted Between 16 and 30 Days After Discharge [ Time Frame: Between 16-30 days after hospital discharge after bowel resection ] [ Designated as safety issue: No ]
  • Percentage of Patients Who Were Readmitted Within 30 Days of Discharge [ Time Frame: Between 0-30 days after hospital discharge after bowel resection ] [ Designated as safety issue: No ]
  • Percentage of Patients Discharged to Various Locations [ Time Frame: Hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Location of discharge for patients who were admitted to the hospital for their bowel resection from home
  • Intensive Care Unit Length of Stay [ Time Frame: Participants were followed up until their hospital discharge after bowel resection ] [ Designated as safety issue: No ]
  • Mortality [ Time Frame: Up to hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    All-cause
  • Proportion of Patients With Reported In-hospital Postoperative Gastrointestinal (GI) Morbidity [ Time Frame: Up to hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    GI morbidity will be identified using International Classification of Disease 9th Edition Clinical Modification (ICD-9-CM) diagnosis and procedure codes for paralytic ileus, flatulence, eructation, gas pain, insertion of a nasogastric tube, total parenteral nutrition, peripheral parenteral nutrition, digestive symptom complications, diarrhea following GI surgery, intestinal obstruction, abdominal pain, peritoneal adhesions, unspecified protein-calorie malnutrition, parenteral infusion of concentrated nutritional substances, or enteral infusion of concentrated nutritional substances.
  • Proportion of patients with in-hospital "other" morbidity [ Time Frame: Up to hospital discharge after bowel resection ] [ Designated as safety issue: No ]
    Other morbidity will be identified using ICD-9-CM diagnosis and procedure codes for cardiovascular morbidity, cerebrovascular morbidity, pulmonary morbidity, infections, thromboembolic events, disruption of wound, decubitus ulcer, or postoperative complications not elsewhere classified.
  • Readmission [ Time Frame: Within 15 days of discharge from hospitalization for bowel resection ] [ Designated as safety issue: No ]
  • Readmission [ Time Frame: Up to hospital discharge after bowel resectionfor bowel resection ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01150760 on ClinicalTrials.gov Archive Site
Postoperative Length of Hospital Stay [ Time Frame: Measured from the day after bowel resection to the day of hospital discharge ] [ Designated as safety issue: No ]
Calendar day of discharge - calendar day of surgery = postoperative length of stay
Not Provided
Not Provided
Not Provided
 
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Comparison of Clinical Outcomes in Bowel Resection Patients Receiving Alvimopan vs. Patients Not Receiving Alvimopan in the Premier Perspective/Care Science Database

Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.

The primary objective of this retrospective observational trial is to assess postoperative morbidity and mortality as reported during the index hospitalization for bowel resection and 15/30-day readmissions of alvimopan vs. non-alvimopan matched patients in the combined Premier/Care Science database(a large medical claims database).

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Retrospective cohort study using the medical claims Premier/Care Science database. The study time frame was from January 1, 2009 through December 31, 2009.

Ileus
Drug: Alvimopan
At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
Other Name: Entereg
  • Alvimopan Users
    Intervention: Drug: Alvimopan
  • Matched controls
Delaney CP, Craver C, Gibbons MM, Rachfal AW, VandePol CJ, Cook SF, Poston SA, Calloway M, Techner L. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection. Ann Surg. 2012 Apr;255(4):731-8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
7050
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ≥ 18 years at discharge
  • Medical claim with an ICD-9-CM procedure code for a primary procedure (identified at position 1 or 2 involving large or small segmental bowel resection with primary anastomosis
  • Discharged within the study dates
  • Surgery at a participating Premier/Care Sciences hospital

Exclusion Criteria:

  • Had a diverting ostomy without a primary anastomosis during the index hospitalization
  • Had a trauma diagnosis
  • Had bowel resections performed on more than 1 day during index hospitalization (this includes cases where a bowel resection and intestinal anastomosis were performed on different days during the index hospitalization)
  • Had an excluded non-bowel resection surgical code (i.e., code for a major non-BR surgical procedure [eg., nephroureterectomy, total joint replacement] in position 1 or 2
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01150760
Premier clinical outcomes
No
Adolor
Cubist Pharmaceuticals
GlaxoSmithKline
Study Director: Lee Techner, DPM Cubist Pharmaceuticals
Cubist Pharmaceuticals
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP